FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W80764682> ?p ?o ?g. }

• W80764682 endingPage "170" @default.
• W80764682 startingPage "161" @default.
• W80764682 abstract "Bortezomib (formerly known as PS-341) inhibits the ubiquitin—proteasome pathway with a hypothesized high degree of specificity for cell-cycle proteins. Preclinical activity has been observed in prostate and mammary cancer. Phase I data have defined tolerable toxicity, and thus analysis for brain tumor therapy is warranted. A rat intracranial 9L gliosarcoma model was given 1.0 mg/kg iv of C-14-labeled bortezomib to assess distribution. Intravenous and intratumoral bortezomib administration 10 d after implant was used to assess efficacy. At 1 h, tumor penetration reached 0.2–0.4 μM concentrations with negligible amounts found in the contralateral normal hemisphere. Survivals of rats given bortezomib 0.1 mg/kg iv twice a week and of controls were 20.8 ± 0.5 and 18.5 ± 0.7 d (p = 0.014), respectively. At 0.2 mg/kg, the bortezomib and control survivals were 22 ± 1.5and 16 ± 0.9 d (p = 0.0045), respectively. The single iv median lethal dose was 0.4 mg/ kg. Intratumoral injections had less toxicity than systemic injections, and 0.2 mg/kg of bortezomib given intratumorally provided benefit over vehicle injection, with survivals of 28 ± 6.4 d and 16.5 ± 0.6 d (p = 0.0013), respectively. In vivo, a single iv dose of 0.2 mg/kg of bortezomib increased 9L tumor p21 protein content 6–24 h after exposure; baseline was reached at 48 h, supporting its impact on the cell cycle. Quantification of intrinsic 20 S proteasome activity in human brain tumors may offer insight into which tumors might respond to inhibitors. Mean 20S proteasome specific activity values (in pmol/s/mg protein) from a small series of frozen fresh human specimens of glioblastoma (GBM), anaplastic astrocytoma, oligodendroglioma, adenocarcinoma, schwannoma, and meningioma were 5.0, 4.6,5.2,8.3,12.0, and 14.3, respectively. A range of values (3.5– 8.2), occurred for GBM (n = 5). It is hypothesized that this measurement may be predictive of the responsiveness of GBM to bortezomib. As a first step, a phase I study of the safety and tolerability of bortezomib has been initiated to determine a maximum tolerated dosage (MTD). In the 9L model bortezomib clearly enhances survival, but at high enough doses systemic bortezomib is not without toxicity. The hypothesized function inhibited by the drug, proteasome activity, is measurable. Therefore, with a MTD in hand, a study correlating this quantity as a predictive surrogate marker with efficacy is possible.Key WordsBrain tumorsproteasome9L gliosarcoma" @default.
• W80764682 created "2016-06-24" @default.
• W80764682 creator A5046742262 @default.
• W80764682 creator A5052115687 @default.
• W80764682 creator A5061676019 @default.
• W80764682 date "2004-01-01" @default.
• W80764682 modified "2023-09-25" @default.
• W80764682 title "Proteasome Inhibitor Therapy in a Brain Tumor Model" @default.
• W80764682 cites W191454705 @default.
• W80764682 cites W1992978957 @default.
• W80764682 cites W2008703656 @default.
• W80764682 cites W2022468096 @default.
• W80764682 cites W2039839254 @default.
• W80764682 cites W2063975188 @default.
• W80764682 cites W2067078624 @default.
• W80764682 cites W2083615074 @default.
• W80764682 cites W2083812880 @default.
• W80764682 cites W2089865526 @default.
• W80764682 cites W2091927567 @default.
• W80764682 cites W2103185055 @default.
• W80764682 cites W2149145595 @default.
• W80764682 cites W2178503716 @default.
• W80764682 cites W2285934609 @default.
• W80764682 cites W4247474225 @default.
• W80764682 cites W4248541288 @default.
• W80764682 cites W2061727101 @default.
• W80764682 doi "https://doi.org/10.1007/978-1-59259-794-9_13" @default.
• W80764682 hasPublicationYear "2004" @default.
• W80764682 type Work @default.
• W80764682 sameAs 80764682 @default.
• W80764682 citedByCount "1" @default.
• W80764682 countsByYear W807646822019 @default.
• W80764682 crossrefType "book-chapter" @default.
• W80764682 hasAuthorship W80764682A5046742262 @default.
• W80764682 hasAuthorship W80764682A5052115687 @default.
• W80764682 hasAuthorship W80764682A5061676019 @default.
• W80764682 hasConcept C126322002 @default.
• W80764682 hasConcept C150903083 @default.
• W80764682 hasConcept C185592680 @default.
• W80764682 hasConcept C207001950 @default.
• W80764682 hasConcept C2776364478 @default.
• W80764682 hasConcept C2777295375 @default.
• W80764682 hasConcept C2777478702 @default.
• W80764682 hasConcept C2778227246 @default.
• W80764682 hasConcept C2778367456 @default.
• W80764682 hasConcept C29730261 @default.
• W80764682 hasConcept C502942594 @default.
• W80764682 hasConcept C71924100 @default.
• W80764682 hasConcept C86803240 @default.
• W80764682 hasConcept C98274493 @default.
• W80764682 hasConceptScore W80764682C126322002 @default.
• W80764682 hasConceptScore W80764682C150903083 @default.
• W80764682 hasConceptScore W80764682C185592680 @default.
• W80764682 hasConceptScore W80764682C207001950 @default.
• W80764682 hasConceptScore W80764682C2776364478 @default.
• W80764682 hasConceptScore W80764682C2777295375 @default.
• W80764682 hasConceptScore W80764682C2777478702 @default.
• W80764682 hasConceptScore W80764682C2778227246 @default.
• W80764682 hasConceptScore W80764682C2778367456 @default.
• W80764682 hasConceptScore W80764682C29730261 @default.
• W80764682 hasConceptScore W80764682C502942594 @default.
• W80764682 hasConceptScore W80764682C71924100 @default.
• W80764682 hasConceptScore W80764682C86803240 @default.
• W80764682 hasConceptScore W80764682C98274493 @default.
• W80764682 hasLocation W807646821 @default.
• W80764682 hasOpenAccess W80764682 @default.
• W80764682 hasPrimaryLocation W807646821 @default.
• W80764682 hasRelatedWork W1862351696 @default.
• W80764682 hasRelatedWork W1989669927 @default.
• W80764682 hasRelatedWork W2064451393 @default.
• W80764682 hasRelatedWork W2079763637 @default.
• W80764682 hasRelatedWork W2135140338 @default.
• W80764682 hasRelatedWork W2796160847 @default.
• W80764682 hasRelatedWork W2899084033 @default.
• W80764682 hasRelatedWork W2983482650 @default.
• W80764682 hasRelatedWork W4253039880 @default.
• W80764682 hasRelatedWork W2611383017 @default.
• W80764682 isParatext "false" @default.
• W80764682 isRetracted "false" @default.
• W80764682 magId "80764682" @default.
• W80764682 workType "book-chapter" @default.